OTC Medicines

Browse OTC Medicines Content

CHPA's most current statement on the recent meeting of the FDA Nonprescription Advisory Committee (NDAC) to evaluate the efficacy of oral phenylephrine (PE).

Sep 7, 2023

CHPA echoed concerns in a letter sent to the U.S. Food and Drug Administration by U.S. Reps. Bob Latta (OH-05), Debbie Dingell (MI-06), and Dan Crenshaw (TX-02), urging the Agency to ensure the simultaneous marketing provision of its proposed rule for Nonprescription Drug Product With an Additional Condition for Nonprescription Use is not included in a final rule.

Sep 6, 2023

The Consumer Healthcare Products Association Educational Foundation today released the following statement announcing the 2023 U.S. Self-Care Marketing Awards finalists. Winners will be announced at the Eighth Annual CHPA Educational Foundation Gala on November 15 at The Bellevue Hotel in Philadelphia. Specific awards will recognize the strategic innovation and marketing expertise of CHPA member companies in the OTC medicine, consumer medical device, and dietary supplement industries.

Sep 5, 2023

A recent national survey of adults conducted by the Bullfinch Group for CHPA further sheds light on consumer awareness, experiences, and perceptions of PE.

Aug 23, 2023

The Consumer Healthcare Products Association (CHPA) Educational Foundation and Family Dollar today announced the launch of a program to help Family Dollar shoppers make informed, educated choices about choosing and using over-the-counter (OTC) products and dietary supplements.

Aug 14, 2023

Bill proposes to make dietary supplements eligible expenses in FSA/HSA accounts, allowing consumers to use tax-preferred health savings to purchase wellness products.

Jul 20, 2023

Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville today released the below statement following the U.S. Food and Drug Administration (FDA) approving Opill®

Jul 13, 2023

CHPA thanks FDA for providing a process to give feedback from industry leveraging science and risk-based approaches to appropriately identify, assess and control (where needed) NDSRIs and preventing unacceptable levels of nitrosamines in drug products.

Jul 3, 2023

Filter Results